AMGN
Price:
$264.49
Market Cap:
$142.17B
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal nu...[Read more]
Industry
Drug Manufacturers - General
IPO Date
1983-06-17
Stock Exchange
NASDAQ
Ticker
AMGN
According to Amgen Inc.’s latest financial reports and current stock price. The company's current ROE is 68.49%. This represents a change of 354.70% compared to the average of 15.06% of the last 4 quarters.
The mean historical ROE of Amgen Inc. over the last ten years is 67.85%. The current 68.49% ROE has changed 0.93% with respect to the historical average. Over the past ten years (40 quarters), AMGN's ROE was at its highest in in the March 2022 quarter at 161.14%. The ROE was at its lowest in in the December 2017 quarter at -16.89%.
Average
67.85%
Median
72.18%
Minimum
7.84%
Maximum
178.97%
Discovering the peaks and valleys of Amgen Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 756.48%
Maximum Annual ROE = 178.97%
Minimum Annual Increase = -69.67%
Minimum Annual ROE = 7.84%
Year | ROE | Change |
---|---|---|
2023 | 107.78% | -39.78% |
2022 | 178.97% | 103.48% |
2021 | 87.96% | 13.93% |
2020 | 77.20% | -4.77% |
2019 | 81.07% | 20.73% |
2018 | 67.15% | 756.48% |
2017 | 7.84% | -69.67% |
2016 | 25.85% | 4.61% |
2015 | 24.71% | 23.49% |
2014 | 20.01% | -12.98% |
The current ROE of Amgen Inc. (AMGN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
124.90%
5-year avg
106.60%
10-year avg
67.85%
Amgen Inc.’s ROE is less than Merck & Co., Inc. (29.27%), less than AbbVie Inc. (65.72%), greater than Gilead Sciences, Inc. (0.65%), less than Johnson & Johnson (20.94%), greater than Bristol-Myers Squibb Company (-36.26%), less than Pfizer Inc. (4.72%), less than Eli Lilly and Company (65.15%), less than Biogen Inc. (10.38%),
Company | ROE | Market cap |
---|---|---|
29.27% | $251.57B | |
65.72% | $317.73B | |
0.65% | $117.09B | |
20.94% | $351.15B | |
-36.26% | $117.15B | |
4.72% | $151.34B | |
65.15% | $755.34B | |
10.38% | $21.72B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Amgen Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Amgen Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Amgen Inc.'s ROE?
How is the ROE calculated for Amgen Inc. (AMGN)?
What is the highest ROE for Amgen Inc. (AMGN)?
What is the 3-year average ROE for Amgen Inc. (AMGN)?
What is the 5-year average ROE for Amgen Inc. (AMGN)?
How does the current ROE for Amgen Inc. (AMGN) compare to its historical average?